<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650415</url>
  </required_header>
  <id_info>
    <org_study_id>CPEPO</org_study_id>
    <nct_id>NCT01650415</nct_id>
  </id_info>
  <brief_title>Erythropoietin Therapy for Children With Cerebral Palsy</brief_title>
  <official_title>Random Control Trial to Evaluate the Safety and Efficacy of Erythropoietin Therapy for Children With Cerebral Palsy -Patient, Principle Investigator, Observer Blind</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bundang CHA Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bundang CHA Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized placebo-controlled trial aims to investigate the efficacy and safety of
      erythropoetin for children with cerebral palsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral palsy is a disorder of movement and posture resulted from a nonprogressive lesion or
      injury of the immature brain. It is a leading cause of childhood onset disability.

      Many experimental animal studies have revealed that erythropoietin is useful to repair
      neurological injury in brain. The main mechanism of erythropoietin is supposed as follows;

        1. Neuroprotection effect

        2. Angiogenesis

        3. Anti-inflammation.

      On the basis of many experimental studies, erythropoietin is suggested as a therapeutic
      method for cerebral palsy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Quality of Movement</measure>
    <time_frame>Baseline - 2 months</time_frame>
    <description>GMPM (Gross Motor Performance Measure) as a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones: alignment, coordination, dissociated movement, stability, and weight shift. The interrater reliability of GMPM subscores and total scores was 0.758-0.886 (subject n=75, tester n=10).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Gross Motor Function</measure>
    <time_frame>Baseline - 2 months</time_frame>
    <description>GMFM (Gross Motor Function Measure) as a standardized measurement tool for assessing Gross Motor Function consisting of 6 sub-scales; lying &amp; rolling, sitting, crawling &amp; kneeling, standing, walking, running &amp; jumping. The measured interrater reliability of GMFM subscores and total scores was 0.974 - 0.997 (subject n=101, tester n=10) and intrarater reliability of GMFM subscores and total scores between one most experienced rater and another newly t rained rater was 0.994 - 1.000 (subject n=101, tester n=2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Neurodevelopmental Outcomes</measure>
    <time_frame>Baseline - 2 months</time_frame>
    <description>K-BSID-II (Korean version of Bayley Scale of Infant Development-II) Motor and Mental Scales. The measured intrarater and interrater reliability of K-BSID-II motor and mental scales was 0.92 - 0.99 (subject n=55, tester n=10).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Motor Development</measure>
    <time_frame>Baseline - 2 months</time_frame>
    <description>AIMS (Alberta Infant Motor Scale)to measure the motor development</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Spasticity</measure>
    <time_frame>Baseline - 2 months</time_frame>
    <description>MAS (modified Ashworth Scale)measured at biceps, hip adductor, hamstring, heel cord</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>Erythropoietin and Rehabilitation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>recombinant human erythropoietin injection and active rehabilitation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Rehabilitation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo erythropoietin and rehabilitation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>twice a week for 1 month</description>
    <arm_group_label>Erythropoietin and Rehabilitation</arm_group_label>
    <other_name>Espogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo erythropoietin</intervention_name>
    <description>twice a week for 1 month</description>
    <arm_group_label>Placebo and Rehabilitation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cerebral Palsy

          -  Abnormal Muscle Tone

          -  Abnormal Brain MRI

          -  Willing to Comply with All Study Procedure

        Exclusion Criteria:

          -  Known Genetic Disorder

          -  Other Etiologies Contributing Developmental Delay

          -  Coagulopathy

          -  Initial high Erythropoietin level in Serum

          -  Previous Erythropoietin Treatment before 3 months

          -  Presence of Drug Hypersensitivity Related to the Study Remedy

          -  Intractable Seizure Disorder

          -  Poor Cooperation of Guardian including Inactive Attitude for Rehabilitation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minyoung Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bundang CHA Hospital</investigator_affiliation>
    <investigator_full_name>MinYoung Kim, M.D.</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Cerebral Palsy</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

